AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05213793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multi-delay arterial spin labeling
Description: Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
Study NCT06473025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on Relative Nutritional Status
Description: The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards
Study NCT06473025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on Returns to Child Nutrition
Description: The intervention involves providing information on the effects of child undernutrition on long-term health, education, and labor market outcomes.
Study NCT06648330 — intervention group
Intervention type: PROCEDURE
Intervention: Paraaortic retroperitoneal lymph node dissection
Description: The relationship between lactate level and mesenteric ischaemia in gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection will be evaluated.
Study NCT06648720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT de-escalation
Description: Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
Study NCT06598384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax combined with Azacytidine
Description: Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5.
Study NCT03289325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine hydrochloride for injection
Description: Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation.
Study NCT03289325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride for injection
Description: Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation.
Study NCT06667895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory gated taVNS
Description: Electrical stimulation will be delivered in bursts during expiration
Study NCT06667895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: random burst stimulation
Description: Electrical stimulation will be delivered in bursts at random timepoints during the breathing cycle
Study NCT06667895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous stimulation
Description: Electrical stimulation will be delivered continuously for 30sec followed by a 30sec break.
Study NCT06667895 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrical stimulation will be identical to the taVNS, but the electrodes will be placed at a different position on the ear
Study NCT06607835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful- compassion
Description: Online mindful-compassion weekly for four weeks
Study NCT06607835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-compassion and cannabis suppositories
Description: Cannabis suppositories and online mindful-compassion for vaginal pain
Study NCT06604234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 in concentration of 1E09 CFU/capsule
Study NCT06604234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator containing maltodextrin
Study NCT06620328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasonography-guided biliary drainage
Description: Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover
Study NCT06620328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasonography-guided biliary drainage
Description: Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover
Study NCT06620549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gastric ultrasonograppy
Description: Patients will be scanned in both supine and right lateral decubitus position (RLD)s. If the antrum is visible, it will be judged if the antrum is empty in both positions or the antrum is empty in supine position and fluid apparent in RLD position suggesting a low fluid volume (\<1,5 ml/Kg). The third option is fluid apparent in both supine and RLD position, suggesting a higher fluid volume (>1,5ml/Kg) and the last option is solid food in one or both positions.
Study NCT06618612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
Study NCT06618612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
Study NCT06618612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PuraPly AM
Description: PuraPly Antimicrobial Wound Matrix is a 2-layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
Study NCT06618612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PuraPly XT
Description: PuraPly Antimicrobial XT Wound Matrix is a 5- layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
Study NCT06619288 — intervention group
Intervention type: DRUG
Intervention: B/F/TAF
Description: Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
Study NCT06619288 — intervention group
Intervention type: DRUG
Intervention: TDF+3TC+EFV
Description: Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
Study NCT06619288 — intervention group
Intervention type: DRUG
Intervention: DTG/3TC
Description: Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
Study NCT06620783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
Study NCT06620783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: yoga
Description: The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
Study NCT06620783 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: active self-care
Description: The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
Study NCT04761549 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adolescent Idiopathic Scoliosis
Description: Adolescent Idiopathic Scoliosis
Study NCT06618131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise program with virtual reality applications for lower extremities
Study NCT06620263 — intervention group
Intervention type: OTHER
Intervention: Pre-education period (PreEd)
Description: No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).
Study NCT06620263 — intervention group
Intervention type: OTHER
Intervention: Post-education period (PostEd)
Description: In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
Study NCT06623760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desk and chair adaptation interventions
Description: Adjustment of the height of tables and chairs to the height of each pupil in accordance with Functional sizes and technical requirements of chairs and tables for educational institutions (GB/T 3976--2014）, with a duration of intervention of one year。
Study NCT06622460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Dexterity Assessment
Description: to evaluate the reliability and sensitivity of the VET in healthy. Their performance helps define normal thresholds and behaviors in grip force modulation and manual dexterity.
Study NCT06621823 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: image-guided surgery technique
Description: The identification of an image-guided surgery technique capable of intraoperatively detecting the presence of lymph node metastases would overcome the disadvantages and complications of extensive staging lymphadenectomies.
Study NCT06619249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation
Description: Long-distance runners will be supplemented with CoQ10 for 4 weeks in cross-over manner with 4 weeks of wash out period.
Study NCT06619249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Long-distance runners will be supplemented with placebo for 4 weeks in cross-over manner with 4 weeks of wash out period.
Study NCT06620692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GM-XANTHO [GM-XAN003]
Description: 5% GM-XANTHO \[GM-XAN003\]
Study NCT06620692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo
Study NCT06618677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOW FODMAPs Diet
Description: patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).
Study NCT06623851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoral scanner
Description: * The digital impressions will be made with the intraoral scanner following the procedure reported by the manufacturer.~* The intraoral scanning process is divided into the lower jaw scan, upper jaw scan, and bite scan stages
Study NCT06623851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alginate impression
Description: Conventional impressions of both arches will be made according to the manufacturer's instructions, using steel impression trays and alginate
Study NCT06622369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Game group
Description: Children in the play group will be allowed to choose a game that is compatible with virtual reality. Children in this group will be allowed to play the game they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use
Study NCT06622369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Cartoon-video group
Description: Children in the cartoon-video group will be allowed to choose a cartoon they want compatible with virtual reality. Children in this group will be allowed to watch the cartoon they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
Study NCT06622681 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06623929 — intervention group
Intervention type: DRUG
Intervention: Etofenamat
Description: E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
Study NCT06623929 — intervention group
Intervention type: DRUG
Intervention: Diclofenac
Description: Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
Study NCT06624254 — intervention group
Intervention type: OTHER
Intervention: lung mechanics, respiratory drive and effort
Description: Patient lung mechanics and respiratory drive and effort will be measured
Study NCT06623604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Physical activity program
Description: In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;#39; classes would not be disrupted.~The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week.~During the program, students did a total of 180 hours of physical activity.
Study NCT06619678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8507
Description: Oral administration
Study NCT06619678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral administration
Study NCT06618833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of medical data
Description: Collection of medical data focused on the history of atrial fibrillation by the principal investigator
Study NCT06618833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collection of global health elements
Description: Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient
Study NCT06618833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS global questionnaire
Description: The patient completes the global PROMIS questionnaire which collects data on their overall health.~The questionnaire consists of 10 questions about the patient\&#39;s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question:~Excellent to poor or Totally to not at all, or Always to never or None to very intense
Study NCT06618833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collection of sociological data
Description: Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator
Study NCT06629233 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor resection
Description: As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
Study NCT06619301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.
Study NCT06619301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
Study NCT05637970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perclose
Description: Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
Study NCT05637970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perclose
Description: Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
Study NCT05637970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Statseal
Description: Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
Study NCT05606315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.
Study NCT05606315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.
Study NCT05606315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.